Earnings call transcript: Paradeep Phosphates Q2 2026 stock falls after slight revenue beat

Paradeep Phosphates reported Q2 FY2027 revenue of INR 7,364 crore, EBITDA of INR 431 crore and PAT of INR 122 crore; revenue was only about 0.02% above forecast. Shares fell 6.58% to INR 129.10 after the results as investors focused on a roughly INR 60 crore inventory write-down, INR 6,700 crore in subsidy receivables and working-capital pressure. Management expects H2 EBITDA per ton of INR 4,500–5,000, versus INR 4,250 in Q2, and said debt should decline substantially by end-December as inventory is sold and subsidy collections improve.

Analysis

The key signal is not the marginal revenue beat; it is whether subsidy timing converts reported sales into cash quickly enough to prevent working-capital needs from overwhelming operating profitability. The inventory write-down also exposes a policy-to-valuation channel: a delayed subsidy decision can impair realizable value before the underlying product is sold. Any later accounting reversal is conditional on notification terms and sell-through, not an automatic earnings tailwind.

Near term (days to weeks), avoid treating the selloff as a clean entry signal or chasing it lower: the unresolved subsidy notifications and high-cost channel inventory leave outcomes binary. Over 1–3 months, the decisive test is actual POS liquidation, collections and debt reduction—not management’s year-end expectation. The shift toward DAP may protect near-term placement where pricing is more favorable, but it risks reinforcing a policy-driven mix that conflicts with balanced-nutrition demand; product mix and subsidy design matter more than aggregate tonnage.

Over 6–18 months, backward integration could reduce exposure to purchased phosphoric acid, but benefits are delayed and execution/capex compete with the need to release cash now. The contrarian risk is that the market may over-penalize a seasonal working-capital peak if collections normalize; conversely, softening raw materials alone will not repair cash conversion if farmer sell-through or subsidy processing lags. No peer-relative valuation or balance-sheet data is supplied to justify a pair trade.

Key Decisions for Investors

• No immediate directional trade; do not buy the dip solely on the small sales beat or management’s claim that conditions are improving.
• Keep Paradeep Phosphates underweight/watchlisted until reported collections and debt provide evidence of cash conversion. Reassess after the promised year-end debt reduction; a failure to fall substantially would falsify the normalization case.
• Track the pending Rabi and sulphur subsidy notifications alongside POS sell-through and inventory valuation. Adverse terms, continued weak liquidation, or further write-downs would support staying cautious; timely collections and stable inventory realization would support reducing the underweight.
• Treat the backward-integration thesis as a longer-dated catalyst, not a near-term earnings offset: monitor commissioning milestones, total capex and funding needs before assigning value to projected savings.